Hironori Harada
Department of Hematology and Oncology
Hiroshima University
Hiroshima
Japan
Name/email consistency: low
- Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. Harada, H., Watanabe, M., Suzuki, K., Yanagita, S., Suzuki, T., Yoshida, Y., Kimura, A., Tsudo, M., Matsuda, A., Tohyama, K., Taniwaki, M., Takeshita, K., Takatoku, M., Ozawa, K. Int. J. Hematol. (2009)
- Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS. Harada, H., Harada, Y., Kimura, A. Curr. Cancer. Drug. Targets (2006)
- Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome. Harada, H., Harada, Y. Crit. Rev. Eukaryot. Gene Expr. (2005)
- High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., Inaba, T. Blood (2004)
- Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Harada, H., Harada, Y., Tanaka, H., Kimura, A., Inaba, T. Blood (2003)